Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

910.86 -13.74 (-1.49%)
Streaming Delayed Price Updated: 2:24 PM EDT, Jul 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
argenex Q2 Earnings Call Highlights ↗
argenex (NASDAQ:ARGX) reported what executives described as one of its strongest quarters to date, driven by continued growth for VYVGART across myasthenia gravis and chronic inflammatory demyelinating... 
Via MarketBeat
Topics Earnings Intellectual Property
News headline image
argenx Eyes More VYVGART Growth as Pipeline Catalysts Near ↗
Executives at argenex (NASDAQ:ARGX) told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic... 
Via MarketBeat
Topics Intellectual Property Supply Chain
News headline image
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference ↗
argenx (NASDAQ:ARGX) Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth,... 
Via MarketBeat
Topics Intellectual Property
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology. 
Via The Motley Fool
News headline image
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials. 
Via The Motley Fool
News headline image
2 Ways to Play the Big Pharma Patent Cliff ↗
With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize. 
Via MarketBeat
Topics ETFs Intellectual Property
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal... 
Via Finterra
Topics Economy
News headline image
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗
Dianthus Therapeutics announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy program based on analysis of data from a part of... 
Via Stocktwits
News headline image
Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability
As of February 26, 2026, the biotechnology sector is witnessing a historic maturation. For years, the industry narrative was dominated by high-burn, pre-revenue innovators searching for a "blockbuster"... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗
This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors. 
Via The Motley Fool
News headline image
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs. 
Via The Motley Fool
News headline image
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a... 
Via Finterra
Topics ETFs Economy Initial Public Offering
News headline image
Beyond the Bot: 2026 Marks the Great Rebalancing as Investors Pivot from AI Hype to Tangible Growth
As the opening bell rings on January 2, 2026, the financial landscape looks fundamentally different from the AI-crazed atmosphere of the previous two years. The "AI Infrastructure Fever" that dominated... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy
As the final trading bell of 2025 rings, the financial markets are closing the year on a high note, characterized by a series of powerful technical breakouts across several high-growth sectors. The S&P... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology
As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
ARGENX SE (NASDAQ:ARGX) Combines Minervini Trend Strength with Explosive Fundamental Growth ↗
ARGENX (ARGX) stock combines strong technical trends with explosive fundamental growth in EPS and sales, making it a high-momentum candidate for investors. 
Via Chartmill
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Argenx SE - ADR (NASDAQ:ARGX) Fits Navellier's 'Little Book' Growth Rules ↗
Argenx SE fits a proven growth stock strategy, showing explosive earnings and sales growth, widening margins, and strong cash flow. 
Via Chartmill
News headline image
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports ↗
Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls. 
Via Investor's Business Daily
News headline image
ARGENX SE - ADR (NASDAQ:ARGX) Shows Strong Growth Traits Matching Navellier's Criteria ↗
Argenx SE shows strong earnings momentum, soaring revenue growth, and high profitability, aligning with Louis Navellier's systematic growth stock criteria. 
Via Chartmill
News headline image
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.